Abstract
Determining the risk that a particular area of hyperplastic breast tissue will progress to cancer is difficult and is currently expressed only as a general risk factor within the population. Using an antibody against the apoptotic purinergic receptor P2X7, we examined 40 cases each of the following histological categories: normal, moderate, florid and atypical hyperplasia, lobular carcinoma in situ, ductal carcinoma in situ, invasive lobular and invasive ductal carcinoma. These were previously diagnosed by H&E and supplied by clinical laboratories as tissue sections. Normal and mildly hyperplastic epithelium was devoid of the cytolytic P2X7 receptors whereas all epithelial cells in all cases of in situ or invasive lobular or ductal carcinoma labelled intensely. The lobular and ductal in situ cases labelled intracellularly while the invasive epithelial cancer cells showed intense cell surface label indicating an attempt was being made to induce apoptosis. All these receptors however are non-functional and thus unable to induce apoptosis. Approximately 10% of all hyperplastic lobules examined in the biopsied tissue, regardless of H&E classification, labelled for P2X7, which is suggestive of early metabolic cancerous change. The acini within lobules were either completely labelled with P2X7 or were completely devoid of the receptor. A potential advantage of this method lies in identifying early cancerous change in hyperplastic lobules and in establishing the true extent of cancerous spread in infiltrating lesions, thus facilitating the task of reporting clear surgical margins.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jarasch ED, Nagle RB, Kaufmann M, Maurer C, Bocker WJ: Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins. Hum Pathol 19: 276–289, 1988
Bodian CA, Perzin KH, Lattes R, Hoffmann P: Reproducibility and validity of pathologic classifications of benign breast disease and implications for clinical applications. Cancer 71: 3908–3913, 1993
Batori M, Gallinaro LS, D'Urso A, Ruggeri M, Lorusso R, Forte A, Fierro N: Papillomatosis and breast cancer: a case report and a review of the literature. Eur Rev Med Pharm Sci 4: 99–103, 2000
Jacobs TW, Connolly JL, Schnitt SJ: Nonmalignant lesions in breast core needle biopsies: to excise or not to excise? Am J Surg Pathol 26: 1095–1110, 2002
Fearon ER: Human cancer syndromes: clues to the origin and nature of cancer. Science 278: 1043–1050, 1997
Cohen SM, Ellwein LB: Genetic errors, cell proliferation, and carcinogenesis. Cancer Res 51: 6493–6505, 1991
Connolly J: Principles of cancer pathology. In: Holland J (ed) Cancer Medicine. Williams and Williams, Baltimore, 1997, p 533
Allred DC, Mohsin SK, Fuqua SA: Histological and biological evolution of human premalignant breast disease. Endocr-Relat-Cancer 8: 47–61, 2001
Russo J, Russo IH: The pathway of neoplastic transformation of human breast epithelial cells. Radiat Res 155: 151–154, 2001
Gong G, DeVries S, Chew KL, Cha I, Ljung BM, Waldman FM: Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization. Clin Can Res 7: 2410–2414, 2001
Mommers EC, van Diest PJ, Leonhart AM, Meijer CJ, Baak JP: Expression of proliferation and apoptosis-related proteins in usual ductal hyperplasia of the breast. Hum Pathol 29: 1539–1545, 1998
Mommers EC, Leonhart AM, Falix F, Michalides R, Meijer CJ, Baak JP, Diest PJ: Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade. J Pathol 194: 327–333, 2001
Alo PL, Visca P, Botti C, Galati GM, Sebastiani V, Andreano T, Di Tondo U, Pizer ES: Immunohistochemical expression of human erythrocyte glucose transporter and fatty acid synthase in infiltrating breast carcinomas and adjacent typical/atypical hyperplastic or normal breast tissue. Am J Clin Pathol 116: 129–134, 2001
Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S: Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 20: 3348–3353, 2001
Diallo R, Schaefer KL, Poremba C, Shivazi N, Willmann V, Buerger H, Dockhorn-Dworniczak B, Boecker W: Monoclonality in normal epithelium and in hyperplastic and neoplastic lesions of the breast. J Pathol 193: 27–32, 2001
Washington C, Dalbegue F, Abreo F, Taubenberger JK, Lichy JH: Loss of heterozygosity in fibrocystic change of the breast: genetic relationship between benign proliferative lesions and associated carcinomas. Am J Pathol 157: 323–329, 2000
Slater M, Lauer C, Gidley-Baird A, Barden JA: Markers for the development of early prostate cancer. J Pathol 199: 368–377, 2002
Slater M, Scolyer RA, Gidley-Baird A, Barden JA: (2003) Increased expression of apoptotic markers in melanoma. Melanoma Res 13: 1–9, 2003
Barden JA, Sluyter R, Gu BJ, Wiley JS: Specific detection of non-functional P2X7 receptors in HEK293 cells and B-lymphocytes. FEBS Lett 538: 159–162, 2003
Moore K, Ray F, Barden J: Loss of expression of purinergic P2X3 and P2X5 receptors in adults with overactive detrusor contractility and urge incontinence. J Neurosci 21: U17–U22, 2001
Slater M, Delprado WJ, Murphy CR, Barden JA: Detection of preneoplasia in histologically normal prostate biopsies. Prost Cancer Prost Dis 4: 92–96, 2002
Parton M, Dowsett M, Smith I: Studies of apoptosis in breast cancer. Br Med J 322: 1528–1532, 2001
Page DL: Cancer risk assessment in benign breast biopsies. Hum Pathol 17: 871–874, 1986
Lennington WJ, Jensen RA, Dalton LW, Page DL: Ductal carcinoma in situ of the breast. Heterogeneity of individual lesions. Cancer 73: 118–124, 1994
Rosen PP, Oberman HA: Tumors of the Mammary Gland. Armed Forces Institute of Pathology, Washington DC, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Slater, M., Danieletto, S., Pooley, M. et al. Differentiation between Cancerous and Normal Hyperplastic Lobules in Breast Lesions. Breast Cancer Res Treat 83, 1–10 (2004). https://doi.org/10.1023/B:BREA.0000010670.85915.0f
Issue Date:
DOI: https://doi.org/10.1023/B:BREA.0000010670.85915.0f